{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-011387","form_type":"8-K","ticker":"PTIX","cik":"0001022899","company_name":"Protagenic Therapeutics, Inc.new","filed_at":"2025-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.170109+00:00","generated_at":"2026-05-21T01:01:36.938642+00:00","sec_items":["1.01","5.03","2.01","3.02","3.03","5.02","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Protagenic Therapeutics acquires Phytanix Bio in share exchange, appoints new CEO and directors","bullets":["Acquired 100% of Phytanix Bio common shares from Alterola Biotech and EMC2 Capital as of May 15, 2025","Issued 117,690 common shares, 5,705 Series C Preferred, 950,000 Series C-1 Preferred, and 20,000 Series D Preferred to Phytanix stockholders","Appointed Barrett Evans as President and CEO, Colin Stott as COO and director, and Jennifer Chao as director; Andrew Slee promoted to Chief Development Officer","Resignations of directors Khalil Barrage, Tim Wright, and Robert Stein effective immediately before closing","Filed certificates of designation for Series C and C-1 Non-Voting Convertible Preferred Stock on May 15, 2025"],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-011387","json":"https://secwatch.observer/filing/0001641172-25-011387.json","markdown":"https://secwatch.observer/filing/0001641172-25-011387.md","text":"https://secwatch.observer/filing/0001641172-25-011387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225011387/0001641172-25-011387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225011387/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-21T01:01:36.938642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0168452889","claim":"Khalil Barrage resigned as Director at Protagenic Therapeutics, Inc.new.","evidence_excerpt":"accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225011387/0001641172-25-011387-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"0aa1115584","claim":"Colin Stott was appointed as Chief Operating Officer at Protagenic Therapeutics, Inc.new.","evidence_excerpt":"Colin Stott as Chief Operating Officer and as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225011387/0001641172-25-011387-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"26dd6e2dc2","claim":"Colin Stott was appointed as Director at Protagenic Therapeutics, Inc.new.","evidence_excerpt":"Colin Stott as Chief Operating Officer and as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225011387/0001641172-25-011387-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4857619268","claim":"Jennifer Chao was appointed as Director at Protagenic Therapeutics, Inc.new.","evidence_excerpt":"Jennifer Chao as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225011387/0001641172-25-011387-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"691bfad299","claim":"Barrett Evans was appointed as President and Chief Executive Officer at Protagenic Therapeutics, Inc.new.","evidence_excerpt":"appointed Barrett Evans as President and Chief Executive Officer, and a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225011387/0001641172-25-011387-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"81a28a2c88","claim":"Barrett Evans was appointed as Director at Protagenic Therapeutics, Inc.new.","evidence_excerpt":"appointed Barrett Evans as President and Chief Executive Officer, and a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225011387/0001641172-25-011387-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"beaf364ede","claim":"Robert Stein resigned as Director at Protagenic Therapeutics, Inc.new.","evidence_excerpt":"accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225011387/0001641172-25-011387-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c3b1c424c5","claim":"Tim Wright resigned as Director at Protagenic Therapeutics, Inc.new.","evidence_excerpt":"accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225011387/0001641172-25-011387-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d25d43a28c","claim":"Andrew Slee changed role as Chief Development Officer at Protagenic Therapeutics, Inc.new.","evidence_excerpt":"promoted Andrew Slee from his prior role of Chief Operating Officer to the Company’s Chief Development Officer, effective immediately upon the Closing on May 15, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225011387/0001641172-25-011387-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Chief Development Officer"}],"fact_type":"executive_change"},{"claim_id":"867a1c8c394a22ffddb2feb627e67aa625a907c8","claim":"Protagenic Therapeutics, Inc.new: Filed Series C-1 Certificate of Designation creating another new series of preferred stock (effective 2025-05-15).","evidence_excerpt":"On May 15, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series C-1 Non-Voting Convertible Preferred Stock (the “Series C-1 Certificate of Designation”) with the Secretary of State of the State of Delaware","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225011387/0001641172-25-011387-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-05-15"}],"fact_type":"governance_change"},{"claim_id":"bb1f86acb4b8a3c0cd95f4c9e78a7eddd6bb793f","claim":"Protagenic Therapeutics, Inc.new: Filed Series C Certificate of Designation creating a new series of preferred stock (effective 2025-05-15).","evidence_excerpt":"On May 15, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series C Non-Voting Convertible Preferred Stock (the “Series C Certificate of Designation”) with the Secretary of State of the State of Delaware","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225011387/0001641172-25-011387-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-05-15"}],"fact_type":"governance_change"},{"claim_id":"6d6373fe1c3618ea91a689f77487de31f5b2a747","claim":"Protagenic Therapeutics, Inc.new completed an acquisition involving Alterola Biotech Inc., EMC2 Capital LLC, and the Preferred Stockholders (closed 2025-05-16).","evidence_excerpt":"On May 16, 2025, the Company completed its business combination with Alterola, EMC2, and the Preferred Stockholders.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225011387/0001641172-25-011387-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Alterola Biotech Inc., EMC2 Capital LLC, and the Preferred Stockholders"},{"label":"Closing","value":"2025-05-16"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}